EFFECT OF CO-ENZYME Q1O ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE-2 DIABETES MELLITUS | UTTAR PRADESH JOURNAL OF ZOOLOGY
Today, India has over 33 million diabetics. Prediabetes disorders such as impaired glucose tolerance and impaired fasting glucose are also on the rise, indicating that the prevalence of diabetes may continue to climb. During the months of August 2015 and February 2016, researchers from Bharath Institute of Higher Education and Research in Chennai, Tamilnadu, conducted research in the departments of pharmacology and medicine (6months). All of the participants were between the ages of 18 and 65. At the start of the trial, the 12th week, and the 24th week, 40 patients were chosen for the study, and their fasting blood glucose, blood HbA1c level, lipid profile (LDL, Triglycerides, HDL, TC), blood coenzyme Q10 level, and BMI were all measured. Each visit to meet the people resulted in a slew of negative situations. The Metformin with Coenzyme Q1O group had lower fasting blood glucose and HbAlc levels at the end of the treatment term, according to the study. In conclusion, patients with type 2 diabetes Mell itus tolerated coenzyme QlO and Metformin well. With more advanced diabetes treatments becoming available, this therapy combining biguanide and coenzyme QlO ensures long-term glycemic control and can provide extra benefits not only in Diabetes but also as an antioxidant in other diseases. Please see the link :- http://mbimph.com/index.php/UPJOZ/article/view/2609